-+ 0.00%
-+ 0.00%
-+ 0.00%

Trade Alert: Principal Accounting Officer Of C4 Therapeutics Kendra Adams Has Sold Stock

Simply Wall St·11/15/2026 12:49:10
语音播报

We'd be surprised if C4 Therapeutics, Inc. (NASDAQ:CCCC) shareholders haven't noticed that the Principal Accounting Officer, Kendra Adams, recently sold US$122k worth of stock at US$2.71 per share. Equally important, that sale actually reduced their holding by a full 93% which hardly makes us feel bullish about the stock.

The Last 12 Months Of Insider Transactions At C4 Therapeutics

In fact, the recent sale by Kendra Adams was the biggest sale of C4 Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that an insider was selling shares at below the current price (US$2.76). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. We note that the biggest single sale was 93% of Kendra Adams's holding.

C4 Therapeutics insiders didn't buy any shares over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

View our latest analysis for C4 Therapeutics

insider-trading-volume
NasdaqGS:CCCC Insider Trading Volume November 15th 2026

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

Insider Ownership Of C4 Therapeutics

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Based on our data, C4 Therapeutics insiders have about 1.0% of the stock, worth approximately US$3.5m. We consider this fairly low insider ownership.

So What Do The C4 Therapeutics Insider Transactions Indicate?

An insider hasn't bought C4 Therapeutics stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we'd only buy after very careful consideration. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Be aware that C4 Therapeutics is showing 2 warning signs in our investment analysis, and 1 of those shouldn't be ignored...

Of course C4 Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.